This technology allows phenotypic screening to discover new compounds and new targets for complex diseases, such as neurodegenerative diseases and cancer
HCS main assets for active cosmetic ingredients
Confirming the efficacy of nutraceuticals and functional food is a key for the development of new compounds. High content in vitro assays play a role in researching and developing new actives ingredients dedicated to human and animals food.
Phenotypic screening by High Content Screening allows analysing toxic events, as genotoxicity, hepatotoxicity, neurotoxicity or cardiotoxicity at the early stage of research.
BIOMIMESYS® 3D technology is a natural HA-based scaffold to better mimic the tissue microenvironment and provide more predictive tools for drug development. The BIOMIMESYS® products are formed by crosslinking reaction of hydrosoluble modified hyaluronic acid and others matrix components with ADH (adipic acid dihydrazide), to mimic the extracellular matrix (ECM). Depending on the organ, ECM components vary and are present in different proportions, allowing a more or less dense and compact cellular environment. BIOMIMESYS® 3D technology allows us to reproduce the cell microenvironment of each organ.
Click here to get more information!
Hepatocytes in primary cultures are still the gold standard in the pharmaceutical industry ; however they are expensive and have a very short lifespan with a progressive loss of specific functions over time. The dipolar Read more…
This year, the ESTIV (European Society of Toxicology In Vitro) congress took place in Berlin and was again a very interesting symposium. The plenary session was open by a presentation on 3D models made by bioengineering Read more…
In this article, researchers from Sorbonne University (Paris, France) proposed an explanation for the patterns followed by breast cancer cells when seeded in BIOMIMESYS, i.e. spherical aggregates. Usually, mathematical models dealing with the formation of Read more…
HCS Pharma will be present to the annual congress of the Society of Study of Blood-Brain Interfaces (SEISC) at Collège de France on Friday, November 9th 2018. The congress will begin by a plenary lecture Read more…
Hyaluronan or Hyaluronic Acid (HA) is a ubiquitous constituent of extracellular matrix (ECM) and, because of its excellent intrinsic biocompatibility and chemical or enzymatic modification versatility, has been widely employed in a multitude of biomedical of Read more…
The 2nd Edition of SLAS advanced 3D human models and High-Content Analysis Conference was a great event with interesting presentations and posters from public labs and various companies. In regards of the different presentations, it Read more…
Last week we attended ELRIG UK Drug Discovery meeting in ExCeL London, and it was a great pleasure for us to present our poster about neurotoxicity testing using HCS there. Many interesting posters were displayed Read more…
Are your interested in meaning full images and high content analysis to asses your compounds properties ? Pierre-Jean, our dermocosmetic expert, will be present at Cosmetic 360 (the international trade fair for innovative ideas and Read more…
The 20th International Congress on In Vitro Toxicology (ESTIV2018) is coming and it will be a great occasion for HCS-Pharma to showcase our current co-development, with the institute du thorax of Nantes and the RHU Read more…
Dans le cadre de notre développement et de l’ouverture d’un second laboratoire à Lille, nous recherchons une apprentie ou un apprenti “business developer” pour le développement des marchés cosmétique, nutraceutique et toxicologique pour le laboratoire de Rennes. La personne aura Read more…
The 2018 Nobel Prize in Physiology or Medicine has been awarded to James Allisson and Tasuku Honjo for their research about immunotherapy to treat cancer. This therapeutic strategy is based on immune checkpoint targeting. Immune Read more…
In HCS Pharma we strongly believe that 3D is the right way to improve drugs dicovery processes. It’s why we develop our 3D hydroscaffold matrix BIOMIMESYS® for 3D cell culture and we invest in 3D Read more…
Nous sommes à la recherche d’un stagiaire BTS pour fin 2018, pour notre site HCS Pharma de Loos. La personne recrutée travaillera sur un projet R&D en oncologie (culture cellulaire et imagerie). Le projet R&D Read more…
Our study director Elodie will attend Drug Discovery 2018 – THE ELRIG‘s flagship conference – which will take place in London next week! We are looking forward to presenting our poster about neurotoxicity testing. Don’t hesitate to visit Read more…
Human and animal microbiota is composed of several type of micro-organism (bacteria, viruses, fungi). Most of them are “commensal” and maintain a symbiotic interaction with their host. Staphylococcus infection is involved in bovine mammary inflammation Read more…
The status of Young Innovative Company (JEI) recognize young companies very active in R&D. this distinction is given by the french ministry of research.
Led by Pr Bertrand Cariou, director of l’institut du thorax*, the project aims at improving the management of hypercholesterolemia by identifying new markers in cardiovascular risk and new targets of LDL-cholesterol metabolism, which plays a central role in the development and progression of cardiovascular diseases.
HCS Pharma – Siège de Lille
Biocentre Fleming Bat A
250 rue Salvador Allende
59120 LOOS
See on map
HCS Pharma – Site de Rennes
Biopole
6 Rue Pierre Joseph Colin
35000 RENNES
See on map
+33 769 999 137
Only for customers please, if you have another interest use the form contact.